MoLEP—Co-creating a Mycobacterium leprae transmission interruption program for the Morogoro region, Tanzania
PLOS Neglected Tropical Diseases · 2025
DOI: 10.1371/journal.pntd.0013507 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, 2025. Verfasst von Tanja Barth-Jaeggi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Swiss Tropical and Public Health Institute, Allschwil, Switzerland. Hauptthemen laut MEDLINE: Leprosy, Disease Eradication, Contact Tracing, Post-Exposure Prophylaxis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis.
Abstract (Originalsprache)
The global goal for leprosy elimination is the interruption of Mycobacterium leprae transmission, resulting in zero new leprosy patients. In alignment with this objective, Tanzania’s updated national leprosy strategy emphasizes early detection, systematic contact tracing, post-exposure prophylaxis (PEP) with single-dose rifampicin (SDR), and integration of services into primary health care. However, the feasibility of accelerating M. leprae transmission interruption in high-burden areas with this strategy has yet to be demonstrated. In 2024, the Morogoro Leprosy Elimination Program (MoLEP) was launched in the country’s most endemic region. Developed through a collaborative process, MoLEP aligns global practices with local conditions and needs. Key interventions include training frontline health workers and expanding contact tracing with SDR-PEP. Furthermore, targeted activities will respond to high transmission areas and the detection of child cases, which serve as indicators of recent transmission. Strengthening the drug supply chain is also a priority. MoLEP will generate critical data on the feasibility and effectiveness of these interventions in accelerating progress toward elimination. The implementation is guided by a comprehensive monitoring and evaluation framework, alongside clearly defined governance structures, to facilitate evidence-informed decision-making. Findings are expected to guide strategic scaling and replication in other high-burden regions across Tanzania and beyond.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Swiss Tropical and Public Health Institute, Allschwil, Switzerland.
- University of Basel, Basel, Switzerland.
- Novartis Kenya Ltd., Nairobi, Kenya.
- German Leprosy and Tuberculosis Relief Association Tanzania, Dar es Salaam, Tanzania.
- National Tuberculosis and Leprosy Programme, Dodoma, Tanzania.
- Novartis Pharmaceuticals, London, United Kingdom.
ORCID-Profile: Tanja Barth-Jaeggi
Förderung
- Novartis
Zitieren
APA
Barth-Jaeggi, T., de Coulon, G., Garimo, I., Msaki, J., Mleoh, L., Kisonga, R., Modali, S., Panchal, S., Njebele, S. M., Sunderji, S., Mageda, K., & Steinmann, P. (2025). MoLEP—Co-creating a Mycobacterium leprae transmission interruption program for the Morogoro region, Tanzania. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0013507
Vancouver
Barth-Jaeggi T, de Coulon G, Garimo I, Msaki J, Mleoh L, Kisonga R, et al. MoLEP—Co-creating a Mycobacterium leprae transmission interruption program for the Morogoro region, Tanzania. PLOS Neglected Tropical Diseases. 2025. doi:10.1371/journal.pntd.0013507
BibTeX
@article{BarthJaeggi2025,
author = {Barth-Jaeggi, Tanja and de Coulon, Guy and Garimo, Issa and Msaki, John and Mleoh, Liberate and Kisonga, Riziki and Modali, Sunil and Panchal, Shaishav and Njebele, Shigela Marco and Sunderji, Shamez and Mageda, Kihulya and Steinmann, Peter},
title = {MoLEP—Co-creating a Mycobacterium leprae transmission interruption program for the Morogoro region, Tanzania},
journal = {PLOS Neglected Tropical Diseases},
year = {2025},
doi = {10.1371/journal.pntd.0013507}
}
EUVIMED